COMMUNIQUÉS West-GlobeNewswire

New Bay Area Lyme Foundation Study Shows Common FDA-Cleared Lyme Tests Miss 64-78% of Early Cases, Underscores Urgent Need for Improved Diagnostics
21/04/2026
Research published in the Journal of Clinical Microbiology PORTOLA VALLEY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a national nonprofit and leading sponsor of tick-borne disease research in [...]
World’s Fastest HIV Test added to the Together TakeMeHome Program for Free at Home HIV Self-Testing Across the United States
21/04/2026
bioLytical’s INSTI® HIV Self Test will support Together TakeMeHome’s national program delivering free HIV self-tests directly to individuals across the United States. Partnership Highlights bioLytical Laboratories Inc. [...]
Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
21/04/2026
ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial [...]
PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing
21/04/2026
Expands access to streamlined genomic data analysis across the PacBio partner ecosystem MENLO PARK, Calif. & BERLIN, April 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a premier developer of sequencing [...]
QHSLab (OTCQB:USAQ) Reports 127% Year-Over-Year ISP Growth and Launches Q-Connect GLP-1 Support Assessment
21/04/2026
Unaudited Q1 2026 ISP revenue of $370,000, up from $163,000 in Q1 2025, representing 127% year-over-year growth Growth supported by expanding provider adoption, the launch of the Q-Connect AOM and GLP-1 Support [...]
Brain Cancer Canada Marks Brain Cancer Awareness Month in May with National Landmark Lightings, Community Events, New Research Investments, and a Call to Action
21/04/2026
Awareness events Research grant awards Gala for Brain Cancer Research with Catherine Wreford and Dr. Cynthia Hawkins TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), the only national charity [...]
XORTX Meets Nasdaq Continued Listing Requirements
21/04/2026
CALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
Sotera Health Announces First-Quarter 2026 Earnings Release Date
21/04/2026
CLEVELAND, April 21, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare [...]
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
21/04/2026
Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” [...]
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
21/04/2026
120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 [...]
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
21/04/2026
This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia’s RESOLVE trial. At 36 weeks, patients in Cohort 9 (n=3) [...]
Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
21/04/2026
BOSTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after U.S. market close. [...]
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
21/04/2026
Two oral presentations including late-breaker at SID Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free remissions Investor [...]
Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026
21/04/2026
First public disclosure of the chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16-dependent Targeted Glue™ degrader of BRD9 AMX-883 is the Company’s lead asset entering a Phase I [...]
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
21/04/2026
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous [...]
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
21/04/2026
Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line models Immune cells activated by Bria-OTS+ exhibit serial killing activity across multiple [...]
BPGbio Appoints Former Oxford Pro-Vice Chancellor for Innovation Chas Bountra, Ph.D., as Executive Vice President and Chief Scientific Officer
21/04/2026
• Former Oxford Pro-Vice-Chancellor for Innovation and former Head of Biology at GSK to lead company’s R&D • Longstanding Scientific Advisory Board Chair steps into an expanded leadership role to accelerate the [...]
Annual General and Special Meeting of Shareholders to be held May 7, 2026
21/04/2026
TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and [...]
Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026
21/04/2026
New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing the systemic tolerability profile Head-to-head non-human primate [...]

Pages